Nutraveris
Thursday, May 23, 2019
Category : NEWS, INGREDIENTS, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

Our Artificial Intelligence solutions, developed by our experts, NOL Datasolution to Create & NOL Compliance to Launch your products, inform you :  

 

Lertal® is an oral nutraceutical containing Perilla frutescens extract, vitamin D3 and quercetin, which has been shown to reduce allergic symptoms in adults. The purpose of this randomized, double-blinded and placebo-controlled study was to evaluate the effects of Lertal® in children with allergic rhinoconjunctivitis.

Effects of a food supplements containing Perilla frutescens, vitamin D3 and quercetin on allergic rhinoconjunctivitis in children.

146 children (9.1 ± 1.88 years) have been enrolled. All participants were treated with standard antihistaminic medication. They were randomly assigned to placebo or to the test product for 4 weeks. The main outcome was the change in Total Symptom Score during the last 12 hours, from baseline to the end of the study.

A reduction in Total Symptom Score has been measured in both groups, without any significant difference between the two groups. However, among the 24 children who experienced symptoms worsening, 8 were in the supplemented group and 16 in the placebo group (p < 0.05). All children with symptoms worsening was poly-allergic children exposed to multiple allergen.

Therefore, this study suggests that Lertal® has no clear effect on treatment of allergic rhinoconjunctivitis in children when used in combination with antihistaminic treatment, but may prevent symptoms worsening in polyallergic chilren.

 

Marseglia GL, Licari A, Ciprandi G, Italian Study Group on Pediatric Allergic Rhinoconjunctivitis. A polycentric, randomized, double blind, parallel-group, placebo-controlled study on Lertal®, a multicomponent nutraceutical, as add-on treatment in children with allergic rhinoconjunctivitis: phase I during active treatment. J Biol Regul Homeost Agents. 2019 Mar-April.33(2):617-622.

 

NUTRAVERIS is the Leading European consultancy on Regulatory & Scientific affairs in Nutrition and Health, founded 13 years ago, to help you formulate, ensure the compliance and substantiation of your products in the 28 EU Member States. 

Thanks to our strong know-how and experience of regulatory compliance, notifications, novel foods, health claims, medical writing,…We, as experts, created Artificial Intelligence solutions, that we use in our everyday missions:

-NOL Datasolution to CREATE new products thanks to Regulatory, Scientific & Marketing data.

-NOL Compliance to LAUNCH products into the different EU member states thanks to automated Compliance analysis, Labeling generation and Monitoring & updating at anytime.

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Tuesday, May 21, 2019
Category : NEWS, REGULATORY | Author : experts | Comment : No Comments
Tags:

Our Artificial Intelligence solutions, developed by our experts, NOL Datasolution to Create & NOL Compliance to Launch your products, inform you :  

Maximum level of citrinin in food supplements based on rice fermented with red yeast Monascus purpureus is currently 2000 µg/kg according to Regulation (EC) 1881/2006.

 

rice fermented with red yeast

A draft regulation that will lower this maximum level for citrinin from 2000 µg/kg to 100 µg/kg has been voted by European Commission and Member States during the Standing Committee on Plants, Animals, Food and Feed – Section Novel Food and Toxicological Safety of the Food Chain on 29 March 2019.

The final text is expected to be published in the coming months.

 

NUTRAVERIS is the Leading European consultancy on Regulatory & Scientific affairs in Nutrition and Health, founded 13 years ago, to help you formulate, ensure the compliance and substantiation of your products in the 28 EU Member States. 

Thanks to our strong know-how and experience of regulatory compliance, notifications, novel foods, health claims, medical writing,…We, as experts, created Artificial Intelligence solutions, that we use in our everyday missions:

-NOL Datasolution to CREATE new products thanks to Regulatory, Scientific & Marketing data.

-NOL Compliance to LAUNCH products into the different EU member states thanks to automated Compliance analysis, Labeling generation and Monitoring & updating at anytime.

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

 +33 2 96 76 54 87

Thursday, May 16, 2019
Category : NEWS, INGREDIENTS, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

Our Artificial Intelligence solutions, developed by our experts, NOL Datasolution to Create & NOL Compliance to Launch your products, inform you :  

 

The aim of this double-blinded, randomized and placebo-controlled study was to examine the effects of an Andrographis paniculata extract in patients with knee osteoarthritis. 103 patients have been enrolled and received a placebo of the extract (ParActin®, 300 or 600 mg/day) for 84 days.

An Andrographis paniculata supplementation reduces joint pain in patients with knee osteoarthritis.

The both doses of supplement have reduced joint pain at days 28, 56 and 84 in comparison to control. Moreover, significant improvements in WOMAC stiffness scores and function scores, as in fatigue score have been measured in both supplemented groups compared to placebo. Finally, quality of life, assessed by the SF-36 questionnaire, and the score of the Functional Assessment of Chronic Illness Therapy have been improved in both supplemented groups.

In conclusion, this study shows that ParActin®, an Andrographis paniculata extract, can reduce joint pain and improve joint function in patients with knee osteoarthritis.

 

Hanckle JL, Srivastav S, Caceres DD, Burgos RA. A double-blind, randomized, placebo-controlled study to asses the efficacy of Andrographis paniculata standardized extract (ParActin®) on pain reduction in subjects with knee osteoarthritis. Phytother Res. 2019 Apr 10.

 

NUTRAVERIS is the Leading European consultancy on Regulatory & Scientific affairs in Nutrition and Health, founded 13 years ago, to help you formulate, ensure the compliance and substantiation of your products in the 28 EU Member States. 

 Thanks to our strong know-how and experience of regulatory compliance, notifications, novel foods, health claims, medical writing,…We, as experts, created Artificial Intelligence solutions, that we use in our everyday missions:

-NOL Datasolution to CREATE new products thanks to Regulatory, Scientific & Marketing data.

-NOL Compliance to LAUNCH products into the different EU member states thanks to automated Compliance analysis, Labeling generation and Monitoring & updating at anytime.

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Monday, May 13, 2019
Category : NEWS, REGULATORY | Author : experts | Comment : No Comments
Tags:

Our Artificial Intelligence solutions, developed by our experts, NOL Datasolution to Create & NOL Compliance to Launch your products, inform you :  

 

The Regulation (EU) 2019/649 of 24 April 2019 amending Annex III to Regulation (EC) 1925/2006 as regards trans fat, other than trans fat naturally occurring in fat of animal origin sets a maximum level of 2 grams per 100 grams of fat for trans fat, other than trans fat naturally occurring in fat of animal origin, in food intended for the final consumer and food intended for supply to retail.

Publication of a regulation limiting trans fatty acids in foods

 

Moreover food business operators supplying other food business operators with food not intended for the final consumer or not intended for supply to retail, shall ensure that supplied food business operators are provided with information on the amount of trans fat, other than trans fat naturally occurring in fat of animal origin, where that amount exceeds 2 grams per 100 grams of fat.

 

Food which does not comply with this Regulation may continue to be placed on the market until 1 April 2021.

 

NUTRAVERIS is the Leading European consultancy on Regulatory & Scientific affairs in Nutrition and Health, founded 13 years ago, to help you formulate, ensure the compliance and substantiation of your products in the 28 EU Member States. 

 

Thanks to our strong know-how and experience of regulatory compliance, notifications, novel foods, health claims, medical writing,…We, as experts, created Artificial Intelligence solutions, that we use in our everyday missions:


-NOL Datasolution to CREATE new products thanks to Regulatory, Scientific & Marketing data.


-NOL Compliance to LAUNCH products into the different EU member states thanks to automated Compliance analysis, Labeling generation and Monitoring & updating at anytime.

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Thursday, May 9, 2019
Category : NEWS, INGREDIENTS, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

Our Artificial Intelligence solutions, developed by our experts, NOL Datasolution to Create & NOL Compliance to Launch your products, inform you :  

 

Propolis may have beneficial effects in type 2 diabetic patients. The aim of this meta-analysis was to examine the available scientific evidences in order to clarify the effects of propolis in these patients.

Propolis may improve glucose control in type 2 diabetic patients

Six randomized and controlled trials, for a total of 373 participants, have been analyzed by the authors. The results of the meta-analysis revealed significant reductions in fasting plasma glucose (-13.51 mg/dl; 95% CI: -24.98, -2.04) and hemoglobin A1C (HbA1c, -0.52%, 95% CI:-0.94, -0.10) concentrations following propolis supplementation. However, no significant effect on insulin concentration has been noted (-0.53 pmol/L, 95% CI: -1.69, 0.63) or insulin sensitivity (HOMA-IR, -0.543, 95% CI: -1.72, 0.64).

Therefore, these results suggest that propolis supplementation may be effective for the short-term (fasting blood glucose) and long-term (HbA1c) management of glucose control in type 2 diabetic patients.

 

Karimian J, Hadi A, Pourmasoumi M, Najafgholizadeh A, Ghavami A. The efficacy of propolis on markers of glycemic control in adults with type 2 diabetes mellitus: A systematic review and meta-analysis. Phytother Res. 2019 Apr 5.

 

NUTRAVERIS is the Leading European consultancy on Regulatory & Scientific affairs in Nutrition and Health, founded 13 years ago, to help you formulate, ensure the compliance and substantiation of your products in the 28 EU Member States. 

Thanks to our strong know-how and experience of regulatory compliance, notifications, novel foods, health claims, medical writing,…We, as experts, created Artificial Intelligence solutions, that we use in our everyday missions:

-NOL Datasolution to CREATE new products thanks to Regulatory, Scientific & Marketing data.

-NOL Compliance to LAUNCH products into the different EU member states thanks to automated Compliance analysis, Labeling generation and Monitoring & updating at anytime.

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87